These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28702148)

  • 21. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
    Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
    Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Identification of low-molecular weight prostate-specific antigen(PSA) and lactoferrin in the prostatic secretion of benign prostatic hyperplasia].
    Xu KX; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Dec; 38(6):648-52. PubMed ID: 17173089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of body mass index on Benign Prostatic Hyperplasia-related complications in patients undergoing prostatectomy.
    Mosli HA; Mosli HH
    Springerplus; 2013; 2():537. PubMed ID: 25674400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
    Pejcic TP; Tulic CDz; Lalic NV; Glisic BD; Ignjatovic SD; Markovic BB; Hadzi-Djokic JB
    Can J Urol; 2013 Apr; 20(2):6707-13. PubMed ID: 23587511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.
    Hammarsten J; Högstedt B; Holthuis N; Mellström D
    Prostate Cancer Prostatic Dis; 1998 Mar; 1(3):157-162. PubMed ID: 12496910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing clinical parameters of abnormal and normal fasting blood glucose in benign prostatic hyperplasia patients.
    Zhao MJ; Huang Q; Wang XH; Ren XY; Jin YH; Zeng XT
    Aging Male; 2020 Dec; 23(5):655-662. PubMed ID: 30739562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
    Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
    Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The correlation between prostate-specific antigen and age. Analysis of prostate-specific antigen values from 4,846 Turkish men with symptomatic benign prostatic hyperplasia.
    Uygur MC; Erol D; Cetinkaya M; Güngen Y; Laleli Y; Altuğ U
    Eur Urol; 1997; 32(4):416-9. PubMed ID: 9412798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients.
    Li BH; Deng T; Huang Q; Zi H; Weng H; Zeng XT
    Am J Mens Health; 2019; 13(4):1557988319870382. PubMed ID: 31426706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
    Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Outcome of Immediate Transurethral Surgery for Benign Prostate Obstruction Patients with Acute Urinary Retention: More Radical Resection Resulted in Better Voiding Function.
    Huang LK; Chang YH; Shao IH; Lee TL; Hsieh ML
    J Clin Med; 2019 Aug; 8(9):. PubMed ID: 31443498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary prostate specific antigen: is the clinical use likely?
    Pejcic T; Hadzi-Djokic J; Acimovic M; Topuzovic C; Milkovic B; Janjic A
    Acta Chir Iugosl; 2005; 52(4):69-74. PubMed ID: 16673599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
    BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.